Last reviewed · How we verify
Experimental: doxycycline
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation. Used for Emerging infectious diseases (investigational indication under ANRS Phase 3 trial).
At a glance
| Generic name | Experimental: doxycycline |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Doxycycline is a tetracycline antibiotic that works by blocking bacterial protein synthesis through reversible binding to the bacterial 30S ribosomal subunit. This prevents the attachment of aminoacyl-tRNA to the ribosome, thereby inhibiting peptide chain elongation. The drug is bacteriostatic, meaning it stops bacterial growth rather than directly killing the organisms.
Approved indications
- Emerging infectious diseases (investigational indication under ANRS Phase 3 trial)
Common side effects
- Photosensitivity
- Nausea and vomiting
- Esophageal irritation
- Vaginal candidiasis
- Diarrhea
Key clinical trials
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions) (PHASE1)
- Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study (PHASE2)
- MyPrEP Plus: Development and Pilot Testing of Novel Preexposure Prophylaxis Decision Support Tools for Transgender Women (NA)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children (NA)
- Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) (PHASE3)
- A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |